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A b s t r a c t  
The basic objectives of this study were to prepare and characterize solid dispersions of poorly 
water-soluble drug fluconazole using hydrophilic carriers by spray drying technique.  
In the present study, a spray drying technique has been used to prepare solid dispersions with 
hydrophilic carriers, mainly  PVP K30and porous carrier Aerosil 200 are used 
Solid dispersions in the form of spray dried powder were characterized in comparison with pure 
drug and corresponding physical mixtures in the same ratios by SEM, IR, DSC, and XRPD studies. 
The absence of fluconazole peaks in XRPD profiles of solid dispersions suggests the 
transformation of crystalline fluconazole into an amorphous form.  the absence of fluconazole peak 
in DSC curves of solid dispersions. The DRIFTS spectra revealed the presence of hydrogen 
bonding in solid dispersions. The in vitro dissolution test showed a significant increase in the 
dissolution rate of solid dispersions as compared with pure fluconazole, spray-dried fluconazole, and 
physical mixtures of drug with hydrophilic carriers. 
It may be concluded that solid dispersions of the purely water-soluble drug fluconazole were 
successfully prepared by spray drying using hydrophilic carriers 
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Introduction 
In pharmaceutical technology there exist numerous drug 
substances, including new chemical entities that in spite of their 
high therapeutic effectiveness are characterized by poor water 
solubility. The latter limits their potential uses in formulating 
bioavailable pharmaceutical products. In all those cases, the rate 
limiting factor for drug absorption becomes the dissolution rate of 
the active ingredient in the gastro-intestinal liquids [14]. Therefore, 
the enhancement of oral bioavailability of such poor water-soluble 
drugs and the preparation of solid oral dosage forms is currently 
one of major objectives and greatest challenges in the area of new 
formulations development. ÂSolid dispersionÊ is one of the earlier, 
yet still favorable, approaches for overcoming this limitation. Owing 
to its simplicity from the manufacturing and process scalability 
stand points, solid dispersion has become one of the most active 
and promising research areas of great interest to pharmaceutical 
companies. Furthermore, such formulations possess considerable 
advantages over other commonly used techniques, especially 
micronization. Hence it is expected that the popularity of solid 
dispersions will grow rapidly [11]. To enhance the dissolution rate, 
increasing the drug solubility is necessary according to the Noyesă
Whitney equation. Various studies have been done in attempt to 
improve solubilities of poorly water soluble drugs; they include 
micronization, solid dispersion, solvent deposition, ordered mixture, 
roll-mixing and complexation. Some of the dissolution- enhancing 
methods have been applied for the production of pharmaceutical  
 
 
preparations. Among these, a solid dispersion is one of the 
effective methods for enhancing the drug dissolution rates. The 
term solid dispersion refers to solid state mixtures, prepared 
through the dispersion, typically by solvent evaporation or melt 
mixing, of one or more active ingredients in an inert carrier matrix 
[13]. In these dispersions, the drug can be present in a fully 
crystalline state (in the form of coarse drug particles), in a semi 
crystalline state, and in fully amorphous state (in the form of a fine 
particle dispersion, or molecularly distributed within the carrier). 
Such systems prove to be very effective for enhancing the 
dissolution rate of low solubility drugs. [12] Pharmaceutical 
materials that are processed by high energy processes such as 
spray drying, spray drying, jet milling, melt extrusion and so forth 
are often rendered at least partially amorphous. This occurs by 
virtue of that these processes create conditions that can prevent 
crystallinization or mechanically disrupt the structure of an existing 
crystalline  material .The high internal energy and specific volume 
of the amorphous state to relative the crystalline state can lead to 
enhanced dissolution and bioavailability, but can also create a 
possibility that is  may spontaneously convert back to the more 
stable crystalline state during processing or storage .As stated 
earlier ,the application of spray drying  technique to obtain 
amorphous form of the drug substances either alone or in 
combination with a hydrophilic polymer is now known .The 
technique has desirable characteristics that the resultant particles 
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are spherical and free flowing The method also offers advantage 
that granulation  and drying are completed in one step[5] 
Fluconazole is antifungal drug, which is often administered orally. 
Fluconazole exhibits very slightly soluble and as a consequence it 
exhibits low bioavailibity after oral administration. Therefore the 
improvement of fluconazole dissolution from its oral solid dosage 
forms is an important issue for enhancing its therapeutic efficiency. 
Fluconazole is insoluble in water which leads to poor dissolution 
rate and subsequent decrease in its gastrointestinal (GI) absorption 
[6]. Results of several investigations revealed that the absorption of 
Fluconazole was limited by its dissolution rate. The formation of 
amorphous forms to increase drug solubility and the reduction of 
particle size to expand surface area for dissolution and decrease 
the interfacial tension with the aid of a water-soluble carrier are 
among the possible mechanisms for increasing dissolution rates 
there by improving bioavailability of poor water-soluble drugs. The 
most commonly used hydrophilic carriers for solid dispersions 
include PEG, PVP, colloidal silicon dioxide, and lipids, such as 
polyglycolized glycerides (Gelucire) [4]. The solvent evaporation, 
melt adsorption, fusion, spray drying, spray freezing, spray 
congealing, melt extrusion, and supercritical fluid precipitation are 
the techniques reported for the preparation of solid dispersions. [7]. 
in the present work, spray drying techniques was used to prepare 
Fluconazole solid dispersions. Hydrophilic carriers like PVP-K30 
using porous carrier Aerosil 200 are used to prepare solid 
dispersions of Fluconazole with different ratios of drug to carrier. 
The pure drug (PD), physical mixture and Solid Dispersion (SD) 
were subjected to DSC, IR and X- Ray Diffraction (XRD) 
spectroscopic studies to elucidate possible crystal changes in 
Fluconazole and drug-carrier interactions. Hence the present study 
was aimed to improve the solubility and/or dissolution rate of poorly 
water-soluble drug through the solid dispersion approach.   
Preparation of Solid Dispersion (SD) 
FLU either alone or in combination with PVP (1:1.1:2 parts by 
weight) was dissolved in sufficient amount ethanol, to clear solution 
proposed quantity of aerosil200 (Table I), was slowly added to 
obtain uniform suspension. Spray drying was carried out using 
laboratory scale spray dryer (LU-20Advanced Model, 
Labultima,Mumbai, India), under the following set of conditions: 
inlet temperature 100oC, outlet temperature, 60 oC, feed rateă6 
ml/min, atomization air pressure  2kg cm/2)and aspiration pressure 
(_200 mm WC) .Physical mixtures (PMs) in the same ratios were 
also prepared, shown in Table 1. Physical characterization and 
dissolution studies of SDs and PMs were performed in comparison 
with pure drug. 
 
Table1-Various solid dispersion batches with different ratios 
prepared by spray drying(SD) & physical mixture(PM) 
 
 
 
 
 
Physicochemical Characterization 
Solubility Measurements  
The saturation solubility of drug and SD with PVPK30 (1:1:1:  and 
1:2:2 w/w) in distilled water and phosphate buffer saline (PBS pH 
7.4) was determined by adding an excess of drug and SD to 10 ml 
distilled water or PBS in glass stoppered tubes. The stoppered 
tubes were rotated for 24 h in water bath shaker at 37oC. The 
saturated solutions were filtered through a 0.45 μm membrane 
filter, suitably diluted with water and analyzed by UV 
spectrophotometer, UV-1601PC, Shimadzu, Japan, . 
Drug content 
Drug Content and Percent Yield Solid dispersions equivalent to 60 
mg of fluconazole were 
weighed accurately and dissolved in a suitable quantity of ethanol. 
The solutions were filtered through a membrane filter (0.45 μm). 
The drug content was determined at 262 nm by UV 
spectrophotometer (UV-1601PC, Shimadzu, Japan,) after suitable 
dilution. Analysis of data were 
done using Disso v 2.08 software. The percentage yield of each 
formulation was also calculated  
Solid State Characterization 
DRIFTS 
The DRIFTS spectra of pure fluconazole, spray-dried fluconazole 
physical mixtures, and solid dispersions were obtained, after 
appropriate background subtraction, using an FTIR spectrometer 
(FTIR-8400, Shimadzu Corp) equipped with a diffuse reflectance 
accessory (DRS-8000, Shimadzu Corp) and a data station. About 2 
to 3 mg of the sample was mixed with dry potassium bromide, and 
the sample was scanned from 4,000 to 400 cm-1. 
XRPD 
The XRPD patterns were recorded on a radiograph diffractometer 
(PW 1729, Philips, Eindhoven, The Netherlands). The samples 
were irradiated with monochromatized Cu Ka radiation (1.542_ A) 
and analyzed between 2 and 50_ (2u). The voltage and current 
used were 30 kV and 30 mA, respectively. The range and the chart 
speed were 5 3 103 CPS and 10 mm/_ (2u), respectively 
DSC 
DSC studies were conducted using a Mettler-Toledo DSC 821e 
instrument equipped with an intracooler (Mettler- Toledo, 
Greifensee, Switzerland). Indium/zinc standards were used to 
calibrate the DSC temperature and enthalpy scale. The samples 
were hermetically sealed into pierced aluminum pans and heated 
at a constant rate of 100C/min over a temperature range of 25 to 
1700C. Inert atmosphere was maintained by purging nitrogen gas 
at a flow rate of 50 mL/min. 
Shape and Surface Morphology  
Type of 
formulation 
Fluconazole Aerosil 
200 
PVPK30
        SD-I 1 1 1
SD-I 1 2 2
PM-III 1 1 1
PM-IV 1 2 2
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The shape and surface morphology of the solid dispersion was 
studied by scanning electron. microscopy (SEM), JEOL, JSM 50A, 
Tokyo, Japan. The samples were mounted on double-sided 
adhesive tape that has previously been secured on copper stubs 
and then analyzed. The accelerating voltage was 5 kV. 
Dissolution Study      
The dissolution studies were performed using a US Pharmacopeia 
type II dissolution test apparatus (Electrolab TDT-06P, Mumbai, 
India). The samples equivalent to 60 mg fluconazole were placed 
in a dissolution vessel containing 900 mL of phosphate buffer (pH 
6.8) maintained 
at 37.6+ 0.50C and stirred at 100 rpm. Samples were collected 
periodically and replaced with a fresh dissolution medium. After 
filtration through Whatman filter paper no. 41, a concentration of 
fluconazole was determined spectrophotometrically at 232.4 nm. 
Data were analyzed by PCPDisso software. 
Results and Discussion 
Table2: Solubility studies of drug and solid dispersions Samples 
 
Solubility Studies and Drug Content 
The results of saturation solubility studies are given in Table 2. The 
solubility of pure drug in water and in PBS (pH 7.4) was found to be 
27.04 μ 0.56 and 57.06 μ 0.67 μg/ml. The solubility of SD using 
PVPK30 (1:1:1:  and 1:2:2 w/w) in water was found to be 46.87 + 
1.24, 57.79 + 1.35μg/ml and in PBS (pH 7.472.76 + 1.21, 81.89 + 
2.35 μg/ml respectively. The drug content of solid dispersion with 
PVPK 30 was found to be in the range of 95 μ 1.45 to 98 μ 2.36% 
.The increases in solubility of fluconazole by PVP K30 probably 
may be due to the formation of soluble complexes between water-
soluble polymeric carrier and poorly soluble drug. And it might be 
attributable to an improvement of wetting of drug particles and 
localized solubilization by the porous carriers.[5,15,17] 
FTIR Analysis 
FTIR is a very powerful technique in detecting presence of 
interaction in drug-carrier solid 
dispersions. The appearance or disappearance of peaks and/or the 
shift of their positions are often indications of interactions such as 
hydrogen bonding.  The intermolecular interaction of complex 
system was established by FTIR. Figure 1 shows Fluconazole 
presenting the characteristic peak of triazole group CH stretching 
.Fluconazole presented characteristic peak at 3116.77 cm-1 was 
due to CH stretching vibration. In 2.4-Difluorobenzyl group at 
1619.34 cm-1 presenting C=C stretching vibration , peak at 
1421.65cm-1 was due to CH2  scissor stretching vibration and peak  
at 1110.86cm-1 was due to C·C stretching vibration. Due to 
solvent peak was show at 916.97, Only representative spectrum is 
shown in, to be Influenced of the incorporation of aerosil200, the 
presence of prominent peak at 1107cm-1, which is hydrogen 
bonding potential of silonal groups located in local environment of 
silica is well documented, In Solid dispersion presented possibility 
of hydrogen bonding between Fluconazole and PVP due to PVP 
has two groups =N, =O that can be potentially form hydrogen bond 
with the drug. At molecular level in SD formulation.However,steric 
hindrance precludes the involvement of nitrogen atom in 
intermolecular interaction, thus making the carbonyl group more 
favorable for hydrogen bonding.[5,9,10] 
Infra-Red spectroscopy(IR) 
 
Batch-I = Pure drug+PVP K30+Aerosil (1:1:1) 
 
Batch-II =Pure drug+PVP K30+Aerosil (1:2:2) 
            Figure 1. DRIFT spectras of pure drug(a) SD-1(b),SD-2(c) PM-3(d),PM-4(e)   
Solubility studies of drug and  
solid dispersions Samples  
Solubility (μg/ml)  
Water  PBS 
Pure drug  27.04 + 0.56  57.06 + 0.67 
SD-1  46.87 + 1.24  72.76 + 1.21
SD-2  57.79 + 1.35 81.89 + 2.35
PM-3  35.59 + 1.12  63.78 + 1.19 
PM-4  36.22 + 1.05  65.12 + 1.13 
Sunita et al. International Journal of Drug Delivery 5 (3) 323-330 [2013] 
 
PAGE | 326 |
 
 
 
Figure. 2. PXRD diffractograms for  pure drug(a) SD-1(b),SD-2(c) PM-3(d),PM-4(e) 
  
Batch-III = Pure drug
Batch-I = drug +PVP K30+Aerosil (1:1:1) 
Batch-II = drug+PVP K30+Aerosil (1:2:2)
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XRD  
The diffraction spectra of fluconazole showed numerous distinct 
peaks indicating presence of high crystalline state. From the X-Ray 
diffraction profile, the characteristic fluconazole peaks with high 
intensity were found to be 2θ at 13.490 14.80, 22.86, 23.98, 24.70, 
26.04, 29.85, 31.42, 32.9. The XRD pattern of solid dispersion of 
sample SD-2 exhibited all the characteristic diffraction peaks of 
fluconazole with lower intensity. This study revealed that the 
crystallinity was reduced to a certain extent in the solid dispersion 
form. Intensity of peak sharpness was reduced in solid dispersion 
compared to pure drug. Various studies have shown that PVP K30 
inhibits crystallinity of drugs and resulting in amorphous nature of 
drug in the solid dispersions. Crystallization inhibition was 
attributed to two effects: interactions, such as hydrogen bonding 
between the drug and the polymer and the entrapment of the drug 
molecules in the polymer matrix during solvent evaporation or a 
combination of both. The solvent was removed during the 
preparation of solid dispersions, viscosity of the system increased 
very rapidly leading to a decrease in drug mobility. When the 
solvent was evaporated completely, drug molecules were frozen in 
the polymer matrix. (Figure. 2) In SDs the characteristic peaks of 
drug disappeared with significant elevation of the diffractograms in 
lower ratios.[5,15] In PMs, the carrier appeared as an elevated 
baseline and the drug produced characteristic diffraction peaks. 
Thermal Analysis 
 
                                                              Batch-III =Pure drug 
 
 
 
 
 
 
 
 
 
                                                          Batch-I =Pure drug+PVP K30+Aerosil (1:1:1) 
 
                                                               Batch-II =Pure drug+PVP K30+Aerosil (1:2:2) 
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                 Figure 3 Differential scanning calorimetry thermograms of Pure drug(a),SD-1(b),SD-2(c)     PM-3(d),PM-4(e) 
 
DSC curves of fluconazole, their physical mixture, and spray-dried 
samples to the amorphicity or crystallinity of fluconazole in the solid 
dispersions are shown in Figure.3. Pure fluconazole gave melting 
endotherms at around indicating that the drug is in cubic crystalline  
form. DSC thermograms of physical mixtures and solid dispersions 
showed the broad endotherms due to water removal at about 100ă 
140.80C. Melting of fluconazole could be observed between 170 
and 180.80C with the physical mixture Figure.3 Melting of 
fluconazole solid dispersions prepared by spray drying processing 
fluconazole not is observed when the ratio of drug to PVP was 
lower than 1:4, which is compatible with their PXRD observations. 
The similarity in DSC curves and PXRD patterns with spray-dried 
samples indicated that fluconazole was amorphously dispersed in 
PVP K30. Because the interaction between fluconazole and PVP 
could be induced during the heating process in DSC programs as 
reported [15,16]. 
 
DSC Studies 
Shape and Surface Morphology  
The SEM results are shown in Figure 4. The surface morphology 
studies revealed that the solid dispersion was closely compacted 
into small spherical form. fluconazole existed in exhibited flat 
broken needles of  different sizes, with well-developed edges 
consisted of large crystalline particles of rather irregular size. On 
the contrary, the solid dispersions appeared in the form of spherical 
particles and the original morphology of components disappeared, 
which supported DSC and XRD data. These results demonstrated 
that fluconazole in solid dispersion was homogeneously dispersed 
into PVP K30 at the molecular level. [5, 15.17] 
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Figure 4.SEM of pure drug(a) SD-1(b),SD-2(c) PM-3(d),PM-4(e) 
 
Dissolution Study 
During dissolution study, pure fluconazole and its PMs showed 
negligible release even after 90 min (Figure.5). Whereas, SDs 
showed drastic increase in dissolution rate with increasing 
concentrations of PVP). Increase in dissolution rate of SDs as 
compared with corresponding PMs was attributed to changes in the 
solid state during the formation of dispersion. It might be owing to 
the formation of high-energy amorphous phase as supported by 
XRPD and DSC data. Thus, fluconazole can be co-spray dried with 
PVP to obtain SDs containing amorphous form of fluconazole. Due 
to anti-plasticizing activity of PVP, viscosity of the binary system 
increases, which thereby decreases the diffusion of drug molecules 
necessary to form crystal lattice [5, 11.17] PMs with PVP did not 
affect the physical state of drug and hence no improvement in 
dissolution characteristics was observed.  
Figure 5. Comparative dissolution profiles of different formulations 
of fluconazole. Each point refers to mean μ SD(n=3), pure drug(a) 
SD-1(b),SD-2(c) PM-3(d),PM-4(e) 
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Conclusion 
It may be concluded that solid dispersions of the purely water-
soluble drug fluconazole were successfully prepared by spray 
drying using hydrophilic carriers. DRIFT spectroscopy revealed the 
possibility of H-bonding interactions in solid dispersions, which was 
also supported by DSC and XRPD observations. The in vitro 
dissolution test showed a significant increase in the dissolution rate 
of solid dispersions as compared with pure fluconazole, spray-dried 
fluconazole and physical mixtures of drug with hydrophilic 
carriers.Therefore, the dissolution rate of the poorly water-soluble 
drug fluconazole can be significantly enhanced by the preparation 
of solids using hydrophilic carriers by the spray drying technique. 
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